TrialCardiovascular diabetology2016

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial.

Yaron Arbel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.